Methods and products for transfecting cells

Patent metadata

Field	Value
Publication number	US-12227757-B2
Application number	US-202217817966-A
Country	US
Kind code	B2
Filing date	Aug 5, 2022
Priority date	Dec 5, 2011
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

First claim

What is claimed is:

1. A method for producing a gene-edited and reprogrammed cell, comprising:
(a) providing a differentiated cell;
(b) culturing the differentiated cell; and
(c) transfecting the differentiated cell with at least one RNA molecule encoding one or more gene-editing proteins, resulting in the differentiated cell expressing the one or more gene-editing proteins, thereby gene-editing the differentiated cell to produce a gene-edited cell; and
(d) transfecting the gene-edited cell of (c) with at least one RNA molecule encoding one or more reprogramming factors, resulting in the gene-edited cell expressing the one or more reprogramming factors;
thereby producing a gene-edited and reprogrammed cell;
wherein (d) occurs in the presence of a medium containing ingredients that support reprogramming of the gene-edited cell to a less differentiated state.

2. The method of claim 1 , wherein the differentiated cell is derived from a biopsy and/or is a human skin cell.

3. The method of claim 1 , further comprising contacting the differentiated cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

4. The method of claim 1 , wherein the medium is substantially free of immunosuppressants.

5. The method of claim 1 , wherein the at least one RNA molecule encoding one or more gene-editing proteins, or the at least one RNA molecule encoding one or more reprogramming factors comprises one or more of a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5-hydroxypseudouridine residue, or a 5-methylcytidine residue.

6. The method of claim 1 , wherein the at least one RNA molecule encoding one or more gene-editing proteins, or the at least one RNA molecule encoding one or more reprogramming factors comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly (A) tail.

7. The method of claim 1 , wherein the one or more reprogramming factors are selected from Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, 1-Myc protein, Tert protein, Nanog protein, and Lin28 protein.

8. The method of claim 1 , wherein the at least one RNA molecule encoding one or more gene-editing proteins comprises a first RNA molecule encoding a first fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease and a second RNA molecule encoding a second fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease.

9. The method of claim 8 , wherein the first fusion protein and the second fusion protein produce a double-strand break in a target DNA sequence.

10. The method of claim 9 , wherein the method further comprises transfecting the cell with a DNA repair template comprising a sequence for insertion and one or more regions of homology to the target DNA sequence, wherein the one or more regions of homology comprise regions upstream and/or downstream of the double-strand break, to result in insertion of the sequence of the repair template in the region of the double-strand break.

11. A method for producing a gene-edited and reprogrammed cell, comprising:
(a) providing a differentiated cell;
(b) culturing the differentiated cell; and
(c) transfecting the differentiated cell with at least one RNA molecule encoding one or more reprogramming factors, resulting in the differentiated cell expressing the one or more reprogramming factors, thereby reprogramming the differentiated cell into a reprogrammed cell in a less differentiated state; and
(d) transfecting the reprogrammed cell of (c) with at least one RNA molecule encoding one or more gene-editing proteins, resulting in the reprogrammed cell expressing the one or more gene-editing proteins, thereby producing the gene-edited and reprogrammed cell;
wherein (c) occurs in the presence of a medium containing ingredients that support reprogramming of the differentiated cell to the reprogrammed cell.

12. The method of claim 11 , wherein the differentiated cell is derived from a biopsy and/or is a human skin cell.

13. The method of claim 11 , further comprising contacting the differentiated cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

14. The method of claim 11 , wherein the medium is substantially free of immunosuppressants.

15. The method of claim 11 , wherein the at least one RNA molecule encoding one or more reprogramming factors, or the at least one RNA molecule encoding one or more gene-editing proteins comprises one or more of a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5-hydroxypseudouridine residue, or a 5-methylcytidine residue.

16. The method of claim 11 , wherein the at least one RNA molecule encoding one or more reprogramming factors, or the at least one RNA molecule encoding one or more gene-editing proteins comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly (A) tail.

17. The method of claim 11 , wherein the one or more reprogramming factors are selected from Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, 1-Myc protein, Tert protein, Nanog protein, and Lin28 protein.

18. The method of claim 11 , wherein the at least one RNA molecule encoding one or more gene-editing proteins comprises a first RNA molecule encoding a first fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease and a second RNA molecule encoding a second fusion protein comprising a DNA-binding domain and a catalytic domain of a nuclease.

19. The method of claim 18 , wherein the first fusion protein and the second fusion protein produce a double-strand break in a target DNA sequence.

20. The method of claim 19 , wherein the method further comprises transfecting the cell with a DNA repair template comprising a sequence for insertion and one or more regions of homology to the target DNA sequence, wherein the one or more regions of homology comprise regions upstream and/or downstream of the double-strand break, to result in insertion of the sequence of the repair template in the region of the double-strand break.

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N2506/09

  from epidermal cells, from skin cells, from oral mucosa cells · CPC title

• C12N2501/91

  Heparin · CPC title